Shire Appoints New Executive
Susan Benton, an industry veteran with more than 25 years of commercial business experience, including 17 years focused in ophthalmology, has been named head of business development, ophthalmics, Shire. She is responsible for business development initiatives stemming from Shire’s organic research and development efforts as well as acquisitions and partnerships.
In 2006, Ms. Benton co-founded Sirion Therapeutics, a fully integrated ophthalmic biopharmaceutical company.
Also joining Shire is Tracey Dawson, a highly experienced healthcare professional with a 17-year track record of sales and marketing success across primary and specialty care medicines.
Ms. Dawson is responsible for developing and leading the overall commercial launch planning process for the ophthalmics business unit. Most recently, she was senior director, global and U.S. marketing at Synageva BioPharma Corp.
Epizyme Appoints President and CEO
Epizyme, a clinical stage biopharmaceutical research and development company creating novel epigenetic therapeutics for cancer patients, has named Robert Bazemore as president and CEO.
Before joining Epizyme, Mr. Bazemore served as chief operations officer of Synageva through its acquisition in July 2015 by Alexion.
Dr. Felix Garzon
Actinium Pharmaceuticals Names Head of Clinical Development
Actinium Pharmaceuticals, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, has appointed Felix Garzon, M.D., Ph.D., to the position of senior VP, head of clinical development.
Dr. Aileen Rubio
Spero Therapeutics Appoints
Head of Biology
Spero Therapeutics LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, has named Aileen Rubio, Ph.D., as head of biology.
Dr. Rubio joins Spero after spending the last decade in positions of increased responsibility at Cubist.
Dr. Rene Russo
Arsanis Names Chief Development Officer
Arsanis Inc., a development-stage biopharmaceutical company focused on monoclonal antibody therapeutics for severe infectious diseases, has appointed Rene Russo, Pharm.D., chief development officer. She was VP, global medical affairs at Cubist Pharmaceuticals, which was acquired by Merck in 2015.
Dr. Deborah Ascheim
Capricor Therapeutics Appoints Chief Medical Officer
Capricor Therapeutics, a biotechnology company focused on the discovery, development, and commercialization of first-in-class therapeutics, has appointed Deborah Ascheim, M.D., to the position of chief medical officer.
Advanced Clinical Adds to Senior Team
Advanced Clinical, a full-service global CRO, functional outsourcing, and strategic staffing solutions provider, has named Bill McGuckin, senior VP, consulting services, to the organization.
Mr. McGuckin brings more than 12 years of consultative sales and leadership experience to Advanced. Before joining Advanced, he was VP of life science and technology at a technology solutions provider.
In other company news, Kimberly Wanick, has been named executive director, compliance and quality, to the organization as well as to its leadership team.
HCB Health Names VP
of Digital Strategy
HCB Health, an independent healthcare advertising agency, has named Joe Doyle as VP of digital strategy. He is charged with overseeing interactive strategy for both of HCB’s offices in Austin and Chicago, and collaborating with his team to develop online solutions including websites, social media campaigns, and online marketing.
Cello Health Makes Executive Appointments
Cello Health BioConsulting has appointed Jim Hall as president. He joins Cello BioConsulting with more than 25 years of experience. Previously, he was a senior partner at Oliver Wyman.
Philip Vorhies has been named VP. He has experience in brand and portfolio strategy, life cycle planning, launch strategy and planning, and forecasting.
Mark Kasakevich has been named a VP at Cello. He has extensive experience in forming, facilitating and leading cross-functional teams.
Jim McDermott joins Cello as VP. He was a senior member of Campbell Alliance’s corporate development practice.(PV)